This article was originally published in The Tan Sheet
FDA and CHPA will co-sponsor a cGMP workshop on drug quality issues. Sessions include Office of Compliance Director David Horowitz on "Current Topics and Progress on the risk based Approach" and FDA district directors on 483 compliance trends. Three separate workshops will be held in Parsippany, N.J. June 6, Chicago July 14 and Santa Monica Aug. 4. Participants can register through the CHPA 1website...
You may also be interested in...
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."